Ascendis Pharma A/S, headquartered in Hellerup, Denmark, is a pioneering biopharmaceutical company focused on developing innovative therapies for rare diseases and endocrine disorders. Leveraging its proprietary TransCon™ technology platform, Ascendis is advancing a diverse pipeline of clinical-stage candidates designed to address critical unmet medical needs. With a strategic emphasis on sustainable growth and patient-centric solutions, the company is poised to make significant contributions to the biopharmaceutical industry, aiming to transform the treatment landscape for patients worldwide. Show more
Location: TUBORG BOULEVARD 12, HELLERUP, DENMARK, 2900, Hellerup, 2900, USA | Website: https://ascendispharma.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE
Market Cap
13.43B
52 Wk Range
$118.03 - $242.00
Previous Close
$219.73
Open
$220.31
Volume
1,331,355
Day Range
$215.51 - $227.18
Enterprise Value
13.7B
Cash
539.1M
Avg Qtr Burn
N/A
Insider Ownership
0.76%
Institutional Own.
-
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
SKYTROFA® (Lonapegsomatropin-tcgd) Details Adult growth hormone deficiency | Approved Quarterly sales | |
YORVIPATH® (palopegteriparatide, developed as TransCon PTH) Details Adult hypoparathyroidism | Approved Quarterly sales | |
SKYTROFA (TransCon hGH) (lonapegsomatropin) Details Pediatric growth hormone deficiency | Approved Quarterly sales | |
TransCon CNP Details Achondroplasia | PDUFA Approval decision | |
TransCon hGH Details Turner syndrome | Phase 3 Initiation | |
TransCon hGH/TransCon CNP combination Details Achondroplasia | Phase 2 Data readout | |
TransCon IL-2 B/y Details Cancer, Solid tumor/s | Phase 2 Data readout | |
TransCon IL-2 B/y + TLR7/8 Details Solid tumor/s, Cancer | Phase 2 Update | |
TransCon TLR7/8 Agonist +/- pembrolizumab Details Solid tumor/s, Cancer | Phase 2 Update | |
TransCon CNP Details Achondroplasia | Phase 2 Update |
